A Novel Process for Developing Fully Human Monoclonal Antibodies - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Novel Process for Developing Fully Human Monoclonal Antibodies
The authors describe a process for generating high affinity, fully human antibodies in culture. Specially selected splenocytes are incubated with cytokines and low levels of antigen, yielding affinity-matured, class-switched B cells. The fully human, specific antibodies produced by these cells can then be cloned and expressed for further characterization.


Pharmaceutical Technology
pp. s28-s31

14. A. Schedl et al., Nucleic Acids Res. 20, 3073–3077 (1992).

15. A. Schedl et al., Nucleic Acids Res. 21, 4783–4787 (1993).

16. A. Schedl et al., Nature 362, 258–261 (1993).

17. L. M. Weiner, J. Immunother. 29, 1–9 (2006).

18. R. Jefferis, Adv. Exp. Med. Biol. 564, 143–148 (2005).

19. R. Jefferis and J. Lund, Chem. Immunol. 65, 111–128 (1997).

20. M. A. Coccia and P. Brams, J. Immunol. 161, 5772–5780 (1998).

21. S. M. Santini et al., J. Exp. Med. 191, 1777–1788 (2000).

22. J. M. Carballido et al., Nat. Med. 6, 103–106 (2000).

23. R. Carlsson et al., J. Immunol. 148, 1065–1071 (1992).

24. C. Lapenta et al., J. Exp. Med. 198, 361–367 (2003).

25. M. Tary-Lehmann, A. Saxon, and P. V. Lehmann, Immunol. Today 16, 529–533 (1995).

26. A. R. T. Gerritsen et al., High Throughput Bio-Layer Interferometry in Therapeutic Antibody Discovery and Development (ForteBio, 2010), http://www.fortebio.com/documents/Genmab_Screening_Europe_2010.pdf, accessed Oct. 2012.

27. Octet Biosensors Product Insert, "Streptavidin High Binding Capacity Biosensors-Kinetics and Screening Grade," (ForteBio, 2007), http://www.fortebio.com/documents/41-0046-PD_Rev_B_Streptavidin_High_Binding_PI.pdf, accessed Oct. 2012.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here